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Abstract
Background: Poly(ADP-ribose) polymerases (PARPs) catalyze the formation of poly(ADP-ribose) (pADPr), a post-
translational modification involved in several important biological processes, namely surveillance of genome integrity, 
cell cycle progression, initiation of the DNA damage response, apoptosis, and regulation of transcription. Poly(ADP-
ribose) glycohydrolase (PARG), on the other hand, catabolizes pADPr and thereby accounts for the transient nature of 
poly(ADP-ribosyl)ation. Our investigation of the interactomes of PARP-1, PARP-2, and PARG by affinity-purification mass 
spectrometry (AP-MS) aimed, on the one hand, to confirm current knowledge on these interactomes and, on the other 
hand, to discover new protein partners which could offer insights into PARPs and PARG functions.
Results: PARP-1, PARP-2, and PARG were immunoprecipitated from human cells, and pulled-down proteins were 
separated by gel electrophoresis prior to in-gel trypsin digestion. Peptides were identified by tandem mass 
spectrometry. Our AP-MS experiments resulted in the identifications of 179 interactions, 139 of which are novel 
interactions. Gene Ontology analysis of the identified protein interactors points to five biological processes in which 
PARP-1, PARP-2 and PARG may be involved: RNA metabolism for PARP-1, PARP-2 and PARG; DNA repair and apoptosis for 
PARP-1 and PARP-2; and glycolysis and cell cycle for PARP-1.
Conclusions: This study reveals several novel protein partners for PARP-1, PARP-2 and PARG. It provides a global view of 
the interactomes of these proteins as well as a roadmap to establish the systems biology of poly(ADP-ribose) 
metabolism.
Background
Poly(ADP-ribose) polymerases (PARPs) catalyze the for-
mation of poly(ADP-ribose) (pADPr), a protein post-
translational modification involved in several important
biological processes, namely surveillance of genome
integrity, cell cycle progression, initiation of the DNA
damage response, apoptosis, and regulation of transcrip-
tion (reviewed in [1]). Recently Kleine et al. [2] limited
the PARP family to PARPs possessing the HYE catalytic
core motif as well as a long β4/β5 loop, namely PARP-1, -
2, -3, tankyrase-1 and -2, and vault-PARP. All other puta-
tive PARP family members were re-classified as mono-
ADP-ribosyltransferases (PARP-6, -7, -8, -10, -11, -12, -
14, -15, and -16) or catalytically inactive members (PARP-
9 and -13). Poly(ADP-ribose) glycohydrolase (PARG), on
the other hand, catabolizes pADPr and thereby accounts
for the transient nature of poly(ADP-ribosyl)ation.
In this study, we chose to investigate PARP-1 and
PARP-2 because of their pivotal role in the maintenance
of genome integrity, and PARG to cover both the synthe-
sis and degradation components of pADPr metabolism.
Through their strand break-dependent PARP activity,
both PARP-1 and PARP-2 are able to initiate a rapid
response to DNA damage via pADPr synthesis on them-
selves (automodification) and on other nuclear acceptors
such as histones. This DNA damage response facilitates
base-excision repair (BER) [3,4] and contributes to non-
homologous end joining (NHEJ) [5,6]. Empirical evidence
however indicates that the functions of PARP-2 do not
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completely overlap those of PARP-1. Indeed, despite the
significant PARP activity provided by PARP-2 in PARP-1
mouse knockout models following genotoxic stimulation
[7,8], these knockouts present several phenotypes associ-
ated with genomic instability [9], demonstrating that
PARP-2 cannot completely compensate for the loss of
PARP-1. Furthermore, double PARP-1/PARP-2 mouse
knockout is lethal at the embryonic stage, indicating that
deficiency in DNA-dependent PARP activity cannot be
functionally compensated for by PARP-3 or any other
PARP family member, at least during early development
[10]. The role of PARG is also vital as it is required for
normal embryonic development and homeostatic cellular
functions, and PARG-null embryos are not viable [11].
The interplay between PARPs and PARG, leading to
marked shifts in the extent of poly(ADP-ribosyl)ation, is a
temporally and spatially complex phenomenon as illus-
trated by the delocalization of PARP-1 from the nucleolus
to the nucleoplasm following DNA damage [12] and the
nucleocytoplasmic shuttling of PARG isoforms [13,14].
The PARPs-PARG system operates as a mechanism sig-
naling DNA strand breaks, in which PARP-1 and PARP-2
play a dual role as damage sensors and signal transducers
to several downstream effectors [15]. Automodified
PARPs relay the signal to effector pathways by recruiting
selected proteins into multiprotein complexes, which
may then either directly participate in DNA repair or
coordinate repair through chromatin unfolding [16]. For
example, repair of single-strand breaks by BER involves a
coordinated series of events wherein the protein XRCC1,
recruited to the injured sites by PARP-1/2, operates as a
scaffold that interacts with and stimulates the activity of
enzymatic components of the BER machinery [17]. We
have conducted a study aiming at the identification
PARP-1/2 and PARG interactomes by AP-MS.
Our AP-MS protocol consisted in the following steps:
A) The protein of interest (PARP-1, PARP-2, or PARG)
was purified from a human cell lysate together with its
binding partners. B) Proteins in the pulled-down com-
plexes were separated by SDS-PAGE and then proteo-
lyzed with trypsin. C) Tryptic peptides were analyzed by
reverse-phase liquid chromatography followed by tan-
dem mass spectrometry (LC-MS/MS) and D) database
searching and statistical analysis were used to interpret
the MS data and to yield the list of proteins that were
present in the immunoprecipitates, including the bait
protein, its interacting partners, and pulled-down con-
taminants. Our investigation of PARP-1, PARP-2, and
PARG aimed to extend current knowledge on these pro-
teins' interactomes by discovering new protein partners
which could offer insights into PARPs and PARG func-
tions.
Results
Identification of proteins associated with PARP-1, PARP-2 
and PARG
Our AP-MS experiments resulted in the identification of
133 protein interactors of PARP-1, PARP-2, and PARG.
Additional file 1 lists these interactors and highlights
whether or not they have been previously reported: green
circles indicate previously reported interactors (a non-
exhaustive list of references is provided) whereas red cir-
cles flag new interactors. We failed to observe some pre-
viously reported PARP-1, PARP-2, and PARG interactors;
those are also included in Additional file 1 (blue circles)
which thus summarizes both the findings of this study
and current knowledge on the interactomes of these pro-
teins. Ninety-one PARP-1 interactors, 42 PARP-2 interac-
tors and 46 PARG interactors were identified; the total,
179, is higher than the number of identified proteins
(133) because many interactors were pulled-down by
more than one pADPr-metabolizing enzyme, as illus-
trated in Figure 1. PARP-1 had both the greatest number
of interaction partners, 91, and of unique partners, 65.
Additional file 2 synthesizes the immunoprecipitation
data, namely the number of unique MS-identified pep-
tides supporting the identification of the interactors and
the protein sequence coverage corresponding to these
peptides. Each of the 179 reported interactions was iden-
tified in at least two different pull-down assays wherein
the interactor was identified by at least two high-confi-
dence peptides (probability of correct identification ≥
95%). In other words, Additional files 1 and 2 do not con-
tain any single-peptide protein, nor any "one pull-down"
protein, which were considered of lower confidence.
Figure 1 Venn diagram illustrating the number of interactors 
identified by AP-MS for PARP-1, PARP-2 and PARG. Numbers out-
side the overlaps correspond to proteins unique to either the PARP-1, 
PARP-2 or PARG immunoprecipitation dataset whereas numbers in-
side the overlaps correspond to proteins common to two or three 
datasets.Isabelle et al. Proteome Science 2010, 8:22
http://www.proteomesci.com/content/8/1/22
Page 3 of 11
AP-MS led to the identification of novel interactions
(Additional file 1, red circles): 69 for PARP-1, 37 for
PARP-2, and 28 for PARG. Among the 179 interactions
identified in this study, 42 have been previously reported
(Additional file 1, green circles); most notable among
these are KU70/KU80, DNA ligase III, DNA-dependent
protein kinase (DNA-PK), Fragile × mental retardation 1
protein (FMR-1), and Nuclear factor kappa B subunit p50
(NFκBp50). These 42 interactions support the validity of
our approach as many of these published interactions
were detected using methodologies orthogonal to AP-
MS. On the other hand, we did not detect 71 known pro-
tein interactors of PARP-1, PARP-2 or PARG (Additional
file 1, blue circles), notably XRCC1 and DNA polymerase
beta in the BER pathway, as well as TP53 and BCL-2 in
the apoptosis pathway.
Complementary immunoblot analyses
In order to check our affinity purification protocol, four
previously reported interactors of PARP-1 and PARP-2
were probed by western blot: Nucleolin, RFC-1 (Replica-
tion factor C subunit 1), and NFκBp50 were probed in
PARP-1 immunoprecipitates while PARP-1 was probed in
a PARP-2 immunoprecipitate. All four proteins were
detected using the antibody against the bait (PARP-1 or
FLAG-PARP-2) but not detected in the control (data not
shown), which supported the validity of our affinity puri-
fication protocol.
Figure 2 presents eleven additional western blots, per-
formed as a complement to AP-MS analysis. Two immu-
noblots verify that the bait was present in its
immunoprecipitate as expected. It was indeed the case
for both PARP-1 (Figure 2A) and FLAG-PARP-2 (Figure
2C). The remaining nine western blots were performed
for new (unreported) protein interactors of PARP-1 and
PARP-2. Firstly, four interactors that had been detected
by AP-MS were probed: BTF (Bcl-2 associated transcrip-
tion factor) in PARP-1 immunoprecipitate (Figure 2A);
and Ku70, Ku80 and FMR-1 (Fragile × mental retardation
protein 1) in FLAG-PARP-2 immunoprecipitates (Figure
2C). Secondly, five interactors absent from the AP-MS
datasets were probed. These corresponded to interac-
tions that were either hinted at by poor AP-MS data (low
confidence identification) or of particular interest to our
research group, namely the interactions between PARP-1
and either AIF (Apoptosis-inducing factor) or FMR-1
(Figure 2B), and between FLAG-PARP-2 and either BTF,
AIF, or STAT1 (Signal transducer and activator of tran-
scription 1) (Figure 2D). The presence of each the probed
interactors was established by immunoblots, although the
signal for AIF in the PARP-1 immunoprecipitate was very
weak (Figure 2). These new interactions are reported as
orange circles in Additional file 1. Finally, the presence of
proteins was also established in the PARG immunopre-
cipitates confirming the findings of Gagné et al. [18] (data
not shown).
Functional analysis using Gene Ontology
The Gene Ontology (GO) project describes the cellular
localizations, molecular functions, and biological pro-
cesses of all annotated human proteins using a standard-
ized vocabulary [19], and thus helps to cluster proteins
into meaningful functional pathways and biological pro-
cesses. Figures 3, 4, and 5 respectively depict the biologi-
cal processes corresponding to the interactors of PARP-1,
PARP-2 and PARG that we have observed by AP-MS
(Additional file 1, green and red circles). Each figure illus-
trates a GO "hierarchical tree": the precise biological pro-
cesses corresponding to the interactors appear as circles
("leaves") at the bottom of the graph and are connected to
progressively broader parent biological processes as one
goes up each "branch" towards the final biological process
"trunk". Circles appearing in the graph are statistically
Figure 2 Complementary western blot analysis of novel PARP-1 
and PARP-2 interactors. A and B) Immunoprecipitation of PARP-1 
and associated proteins. In A) immunodetection of PARP-1 (bait) and 
the novel interactors Btf, identified by AP-MS. In B) immunodetection 
of novel PARP-1 interactors FMR-1 and AIF, absent from AP-MS. C and 
D) Immunoprecipitation of PARP-2 and associated proteins. In A) im-
munodetection of PARP-2 (bait) and the novel interactors KU70, KU80 
and FMR-1, identified by AP-MS. In B) immunodetection of novel 
PARP-2 interactors BTF, AIF and STAT-1, absent from AP-MS. Each im-
munodetection is done in whole cellular extract (WCE) and immuno-
precipitates (IP) from control (CTRL) and the bait (PARP-1 or FLAG-
PARP-2).
Figure 3 Gene Ontology analysis of PARP-2 interactors. Gene On-
tology classification by biological process of the interactors of PARP-2 
identified by AP-MS. See text for details.Isabelle et al. Proteome Science 2010, 8:22
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over-represented biological process GO terms, as deter-
mined by the Biological Networks Gene Ontology tool
(BiNGO). The size of each GO term's circle is propor-
tional to the number of interactors corresponding to this
term, and the color shading indicates the degree of statis-
tical significance (a darker shade indicates higher signifi-
cance). The protein interactors belonging to each branch
are listed underneath it. For concision, only the abbrevia-
tions of the genes encoding these proteins are listed.
These abbreviations precede the protein names in Addi-
tional file 1.
Discussion
As previously mentioned, our investigation aimed to con-
firm current knowledge on the interactomes of PARP-1,
P ARP-2, and P ARG as well as to discover new protein
partners which could improve our understanding of into
the functions of these key proteins. It was also hoped that
a global view of the PARP-1, PARP-2 and PARG interac-
tomes may help to grasp the ramifications of cancer treat-
ment by PARP inhibitors, either in terms of therapeutic
efficiency or side effects. Indeed, while PARP inhibitors
have been recently shown to be active anticancer agents
in BRCA1- and BRCA2-mutant tumors [20], fairly basic
biological questions - including the biological roles of
some of the interactors of PARP-1, PARP-2, and PARG -
remain to be answered. Several PARP inhibitors are cur-
rently undergoing clinical trials and should be marketed
as mid-stage results are promising (reviewed in [21]).
Intrinsic strengths and limitations of AP-MS
Compared to yeast two-hybrid and related methods his-
torically used to define protein interactomes, AP-MS has
three major advantages. Firstly, it can be performed
under near physiological conditions, in the relevant
organism and cell type. Secondly, it does not typically
affect post-translational modifications, which are often
crucial for the organization and activity of complexes
[22]. And thirdly, mass spectrometers can detect every
abundant protein present in the immunoprecipitate,
whether or not its presence is expected. Western blots,
for instance, though very sensitive and specific, are inca-
pable of that: they only target a few selected proteins
expected to be in the sample from prior knowledge, and
are therefore not conductive to the discovery of new,
unanticipated protein interactors. Every analytical meth-
odology - and AP-MS is no exception - possesses unique
strengths and limitations, notably in terms of the number
of different analytes it can detect simultaneously, and of
its potential for false negatives and false positives.
False negatives, or "where did the interactors go?"
As pointed out by Gingras et al[22], high-throughput AP-
MS datasets typically lack many previously documented
protein-protein interactions. This was notably observed
for two comprehensive AP-MS studies in yeast [23,24]
and it is clearly the case of the current study's dataset as
we failed to detect a number of known protein interaction
of PARP-1, PARP-2 and PARG. Four factors likely con-
tribute to this lack of detection [22]: 1) the proteins may
not interact under the tested conditions; 2) when a bait is
expressed with a tag, the nature and location of the tag
may disrupt certain interactions; 3) the conditions of the
AP bee too harsh to preserve interactions; and 4) the lack
of detection may be due to a problem with the relative
abundance of proteins in the AP sample. The latter typi-
cally occurs if the bait is in large molar excess over its
interacting partners (a problem that is exacerbated when
the bait is overexpressed, as in our case) or if the prey is in
much lower abundance than other components of the
sample (low stoichiometry). AP-MS thus tends to capture
more stable and fairly abundant interactors, in contrast to
other targeted approaches such yeast two-hybrid assays
[22]. Finally interactions detected with western blots may
not be detectable by AP-MS since western blot is gener-
ally more sensitive than MS for protein detection. We
recognize that our investigation most probably missed
certain low-abundant and/or low-affinity interactors of
PARP-1, PARP-2 and PARG, and that more sensitive
Figure 4 Gene Ontology analysis of PARP-2 interactors. Gene On-
tology classification by biological process of the interactors of PARP-2 
identified by AP-MS. See text for details.
Figure 5 Gene Ontology analysis of PARG interactors. Gene Ontol-
ogy classification by biological process of the interactors of PARG iden-
tified by AP-MS. See text for details.Isabelle et al. Proteome Science 2010, 8:22
http://www.proteomesci.com/content/8/1/22
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techniques will likely expand their interactomes in the
future.
False positives, or "are the reported protein-
proteininteractions real?"
Lack of specificity, i.e. reporting protein interactions that
do not exist in the affinity-purified sample, may stem
from either unspecific binding or incorrect protein iden-
tification. In the former case, immunoprecipitation mate-
rial and reagents such as protein G, antibodies, or beads
bind to proteins which are then falsely reported as bind-
ing the bait. In this study, two measures were taken to
avoid reporting such non-specific interactions. Firstly, as
detailed in Materials and Methods, BSA was added to the
antibody-bead complex; BSA thus acted as a strong com-
petitor (blocking agent) for all non-specific binding sites.
Secondly, control immunoprecipitations using mouse
immunoglobulin G as a bait were systematically used to
discriminate between non-specific interactions and bona
fide bait interactors. Proteins present in the controls were
not reported. Reporting incorrectly identified proteins
interactors was minimized through the use of stringent
acceptance criteria for peptide and protein MS identifica-
tions, as described in Materials and Methods. Indeed, all
reported peptide identifications have a probability of cor-
rect identification greater than 95%, and all reported pro-
tein identifications have a probability of correct
identification greater than 99% and at least two accepted
peptides. With these acceptance criteria, the overall MS
false positive rate is estimated to be lower than 1%; in
other words, the number of reported false positives due
to incorrect protein identification should not exceed two.
Mass spectrometry is widely recognized as a reliable
method of identification of proteins in biological samples
when the identifications are statistically validated and the
false positive rate is kept low (reviewed in [25-27]). The
use of Scaffold [28] to achieve such a statistical validation
is also widely accepted with more than 40 recent peer-
reviewed publications containing Scaffold-validated pro-
tein identifications. The fact that replicate AP-MS experi-
ments were performed also increases confidence in the
v a l i d i t y  o f  t h e  r e p o r t e d  i n t e r a c t i o n s  a s  t h e y  w e r e  a l l
observed twice or more.
Interpretation of the interaction datasets
A few points should be kept in mind while interpreting
the PARP-1, PARP-2 and PARG datasets reported in
Additional file 1. The first point is that AP-MS cannot
distinguish between direct and indirect interactions; that
is, reported interactions may correspond to two proteins
which interact directly or, probably more frequently, cor-
respond to two proteins which interact indirectly, via one
or more bridging molecules (proteins, nucleic acids, or
other molecules). The second point relates to overexpres-
sion of the bait. Transient over-expression of FLAG-
PARP-2 and FLAG-PARG was required to circumvent the
low specificity of available anti-PARP-2 and anti-PARG
antibodies whereas FLAG-PARP-1 was transiently over-
expressed for some of the PARP-1 experiments, in the
hope of pulling some weak and/or scarce interactors of
PARP-1 above detection limit. Such overexpressions may
have resulted in the association of the bait protein with
chaperones and could have led to improper intracellular
localization [22]. Finally, one must keep in mind that
some protein-protein interactions detected in a cell lysate
may not actually occur in vivo if the two protein partners
never co-localize within the cell.
PARP-1 and PARP-2 may bind some proteins through their 
pADPr moiety
The PARP-1 and PARP-2 used as baits may have pre-
sented some degree of automodification, in which case
their pADPr moiety - rather than their protein interac-
tion domains - may have bound some protein interactors.
Gagné  et al. recently investigated the interactome of
pADPr by AP-MS and reported a large number of
pADPr-binding partners [29]. Interestingly, the interac-
tors of PARP-1, PARP-2 and PARG listed in Additional
file 2 include 53 of these pADPr-binding partners, and
thus support the above hypothesis. These 53 common
interactors are presented in Additional file 3 and consist
mostly of DNA/RNA-binding proteins such as ribonu-
cleoproteins, translation initiation factors, helicases, and
ribosomal proteins.
Functional analysis using Gene Ontology
BiNGO analysis suggests that PARP-1 may be involved in
more biological processes than PARP-2 or PARG. Indeed,
whereas all three enzymes are involved in RNA process-
ing and both PARP-1 and PARP-2 participate in DNA
repair, glycolysis and apoptosis, only PARP-1 partakes in
cell cycle regulation and ubiquitin conjugation. The
involvement of PARP-1 in DNA repair and apoptosis is
well known (reviewed in [1]) and was expected. However,
its apparent interaction with glycolysis and RNA metabo-
lism proteins is surprising and may point to new PARP-1
functions. Devalaraja-Narashimha and Padanilam [30]
recently studied the impact on glycolysis of the inhibition
of glyceraldehyde phosphate-3-dehydrogenase by PARP-
1, while others have focused on how NAD consumption
(energy depletion) by PARP-1 influenced glycolysis [31-
33]. PARP-1 is responsible for the majority of pADPr for-
mation following DNA damage and excessive pADPr for-
mation promotes shuttling of AIF to the nucleus and
caspase-independent cell death [34]. The detailed mecha-
nism is yet to be understood, but it has been suggested
that pADPr may be shuttled from the nucleus to the cyto-
plasm via proteins, resulting in AIF translocation, as well
as the sequestration of anti-apoptotic proteins or the acti-
vation of pro-apoptotic proteins [35,36]. The "apoptosis"Isabelle et al. Proteome Science 2010, 8:22
http://www.proteomesci.com/content/8/1/22
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branch of Figure 4 suggests that P ARP-2 probably also
plays a role in apoptosis, presumably because it can also
add pADPr to proteins. PARP-2 apparently plays a less
important role in apoptosis than PARP-1 given the lower
complexity of PARP-2's apoptosis branch. The biological
processes shown for PARG in Figure 5 are mainly linked
to RNA metabolism and confirm the findings of previous
s t u d i e s .  I n d e e d ,  w i t h  t h e  m a j o r i t y  o f  P A R G  a c t i v i t y
located in the cytoplasm, maintaining tight spatial regula-
tion of this enzyme depends on nucleocytoplasmic shut-
tling proteins such as the ribonucleoprotein (RNP)
complexes [18]. Moreover, poly(ADP-ribosyl)ation of
heterogenous nuclear ribonucleoproteins (hnRNPs) was
determined to be of importance for protein splicing in
Drosophila, suggesting that PARP-1 and PARG modulate
splicing pathways through regulation of interactions
between hnRNPs and RNA [37].
Involvement of PARP-1, PARP-2 and PARG in RNA 
metabolism
Figures 3, 4 and 5 indicate that PARP-1, PARP-2 and
PARG are all involved in RNA metabolism and, more pre-
cisely, in RNA splicing. For instance, hnRNP M and
hnRNP U, which are both part of the spliceosome C com-
plex [38], are among the 11 pulled-down proteins com-
mon to PARP-1, PARP-2 and PARG. Moreover, PARP-1,
PARP-2 and PARG also interact with several other mem-
bers of this complex (Additional file 1). PARP-1 interacts
with splicing factor 3A1, splicing factor 3B2, splicing fac-
tor 3B1, hnRNP C, snRNP EFTUD2 and U5 snRNP 200
kDa; PARP-2 with DEAD box polypeptide 48, ATP-
dependent RNA helicase DDX5, hnRNP A1, hnRNP G
and Polyadenylate-binding protein 1; and PARG interacts
with ATP-dependent RNA helicase DDX5, hnRNP A1,
hnRNP Q, hnRNP A2B1 and Polyadenylate-binding pro-
tein 1. Many of these proteins share interactions with
more than one pADPr-metabolizing enzyme. The fact
that each bait pulled down different components of the
spliceosome C complex might be explained by the
d y n a m i c  n a t u r e  o f  t h i s  c o m p l e x  b u t  i s  m o r e  p r o b a b l y
indicative of a lack of affinity for the bait, or of a lack of
analytical sensitivity.
Our dataset includes other interesting PARP-1 interac-
tors related to transcription and splicing, namely the
THO/TREX and FMRP complexes. THO complex sub-
units 1, 2, 5 and 6 were identified by mass spectrometry
in PARP-1 immunoprecipitates. THO/TREX is required
for the nuclear export of mRNA and is coupled to tran-
scriptional elongation [39,40]. The THO complex is com-
posed of multiple subunits linked to Aly and Bat1, which
form the TREX complex responsible for RNA export.
The THO/TREX complex is also recruited to splice
mRNA, and is indirectly associated to transcription via
the splicing machinery [41]. Many components of the
FMRP complex, which suppresses translation of selected
mRNA within large mRNP complexes [42], are present in
our dataset: Fragile-X mental retardation syndrome-
related protein 1 (FXR1) (common to PARP-1, PARP-2
and PARG datasets); FXR2 and FMR1 (PARP-2 and
PARG); and nuclear Fragile-X mental retardation-inter-
acting protein 2 (PARG only). While PARP-1 [43] and
PARG [18] have already been identified in mRNP com-
plexes, their role therein remains unclear although some
evidence pointed toward pADPr regulation of transcrip-
tional activity. Our finding that PARP-1 and PARP-2 are
associated with FMRP particles strengthens this hypothe-
sis. Both PARP-2 and PARG also interact with nuclease-
sensitive element-binding protein 1 (YBX-1), which is
involved in mRNA binding, regulation of mRNA stability,
translation efficiency and, possibly, binding splicing
enhancer elements [44,45].
The involvement of PARP-1, PARP-2 and PARG in the
regulation of RNA splicing is corroborated by many stud-
ies. Recently , Ji and T ulin [37] demonstrated in Droso-
phila that endogenous PARP-1 and PARG regulate
pADPr binding to hnRNPs, subsequently altering the
RNA-binding ability of hnRNPs and modulating splicing.
Another study by Malanga et al. [46] confirmed that
pADPr can bind the splicing factor ASF/SF2 within
domains crucial for splicing activity, thereby regulating
splicing. pADPr is also involved in transcription-splicing
through its role in Cajal bodies [47]. Small spliceosomal
components first accumulate in Cajal bodies and then
undergo a spliceosome phase assembly; they are then
transported to the cytoplasm for splicing events and are
finally reintegrated to Cajal bodies to be recycled [48,49].
Automodified PARP-1 is responsible for protein shuttling
into Cajal bodies and PARP-1 is itself crucial for the
integrity of Cajal bodies [47]. Furthermore, PARG dele-
tion leads to an imbalance of proteins in the Cajal bodies,
demonstrating that pADPr is an important regulator of
shuttling into Cajal bodies. As illustrated above, PARP-1,
PARP-2 and PARG share several interactors related to
splicing and transcription, and poly(ADP-ribosyl)ation,
or pADPr binding, presumably underlies these interac-
tions. Indeed, and as mentioned previously, many inter-
actors of PARP-1, PARP-2 and PARG identified in this
study are also known to be associated with pADPr [29].
One can hypothesize that PARP-1, PARP-2 and PARG
regulate some transcriptional and splicing events through
the addition and subsequent removal of pADPr chains on
specific substrates.
Dual DNA-dependent roles of PARP-1 and PARP-2: DNA 
damage signaling and cell death
It is well known that genomic stress induces pADPr for-
mation via DNA-dependent PARP activation. As the
severity of DNA strand breaks increases, more pADPr isIsabelle et al. Proteome Science 2010, 8:22
http://www.proteomesci.com/content/8/1/22
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synthesized and the extent of poly(ADP-ribosyl)ation
determines the cellular response: mild genotoxic stress
induces PARP-1 and PARP-2 activation and signaling to
promote DNA repair while severe stress generates
extreme pADPr accumulation that triggers cell death.
DNA damage signaling
BiNGO analysis revealed similar significance for the
"DNA repair" branches of PARP-1 and PARP-2 (Figure 3
and 4). Both PARP-1 and PARP-2 immunoprecipitates
contained KU70 and KU80, two proteins involved in
DNA double-strand break repair by NHEJ, thus confirm-
ing the redundant function of PARP-1 and PARP-2 in the
surveillance of genome integrity. Other interactors linked
to the DNA repair function of PARP-1 and PARP-2 are
RNA-binding protein 14 [50] (observed for both PARPs)
and Replication factor C (RFC) subunits 1, 2, 3, 4 and 5
(observed for PARP-1 only). RFC1, RFC2, RFC3, RFC4
and RFC5 form a heteropentamer complex that interacts
with PCNA and enables the binding of its N-terminal
DNA-binding domain to duplex DNA. This mechanism
is essential in the recognition of non-primer template
DNA structures during replication and/or repair [51].
PARP-2 interactors also include Replication Factor A
protein 1 and the catalytic subunit of DNA-dependent
protein kinase (DNA-PK). The former protein partici-
pates in the very early stages of initiation in both DNA
recombination and DNA replication, through association
with DNA-PK and, possibly, through the recruitment of
NHEJ proteins [52]. Globally, our interactor datasets are
consistent with the known roles of PARP-1 and PARP-2
in DNA repair initiation via the BER [4,53,54] and NHEJ
[5,55] pathways. Our results suggest that PARP-1 and
PARP-2 may signal DNA damage by means of multiple
complexes in order to speed up DNA repair.
Cell death
As previously mentioned, activation of the DNA-depen-
dent PARP-1 and PARP-2 under severe genomic stress
leads to substantial accumulation of pADPr, which trig-
gers AIF translocation, and eventually cell death [34]. Our
study reveals some unknown details of this apoptotic
pathway. For instance, GRP78, HSC70, HSP90AB1, and
HSP70, four heat shock proteins, are all interactors of
PARP-1, PARP-2, and PARG. Although heat shock pro-
teins are frequent immunoprecipitation contaminants
[56], the above four proteins were absent from our con-
trol datasets and we consequently believe them to be
bona fide interactors. These heat shock proteins act as
chaperones and are likely to attach to multiple unrelated
proteins, given that they bind mutated and unfolded pro-
teins to prevent their secretion. However, some heat
shock proteins exhibit interactions or functions similar to
PARP-1 and PARP-2, notably in apoptosis. For instance,
GRP78 is involved in the negative regulation of apoptosis
by suppressing the activation of caspase-7 and caspase-12
[57] while HSC70, an anti-apoptotic co-chaperone, inhib-
its HSP90 and other apoptotic proteins [58]. HSP90AB1
interacts with TP53 within a multi-chaperone complex in
which HSP70 plays an important role in the process of
apoptosis [59]. The heat shock protein 60kDa mitochon-
drial (HSP60) is another interactor that is shared by
PARP-1 and PARP-2. One of the known functions of
HSP60 is its contribution to the regulation of apoptosis
through its association with caspase-3 [60] and BAX [61].
Also of interest among PARP-1 interactors are Baculovi-
ral IAP repeat-containing protein 6 (BIRC6) and BTF.
The latter binds to DNA and represses transcription of
survival genes [62], while BIRC6 is an inhibitor of apopto-
sis through its inhibition of caspases, particularly of cas-
pase-3 [63].
An interesting hypothesis yet to be confirmed is that
poly(ADP-ribosyl)ation affects multiple proteins in order
to shift the balance between pro-apoptotic and anti-
apoptotic molecules. Indeed, interfering with NAD and
pADPr metabolism increases mRNA and protein GRP78
levels [64,65]. Parp-1-/- fibroblast cells exhibit increased
expression of HSP70 [66], a protein that delays nuclear
translocation of AIF [67]. Moreover, increased levels of
HSP70 reversibly inactivate PARG, and thus cause pADPr
accumulation [66]. Our observation of likely protein
interactions between PARP-1/2 and some heat shock
proteins raises the possibility that these PARPs could
affect the function of heat shock proteins during apopto-
sis through transcriptional regulation.
A possible new function for PARP-1
The role of pADPr in the cell cycle is generally associated
with mitotic spindle functions. This structure consists of
an array of microtubules and various molecules that self-
organize to align and then segregate chromosomes dur-
ing mitosis. pADPr is found at the spindle and is required
for its function [68]. Our data highlights that another
possible role of PARP-1 in the cell cycle, as the regulation
of the APC/C complex. Indeed, we report here for the
first time that PARP-1 interacts with eight of the twelve
proteins belonging to the APC/C complex, one of the two
poly-ubiquitylating E3 ligase complexes influencing cell
cycle progression. APC/C is largely associated with cell
cycle progression and sister chromatid separation
(reviewed in [69]). The four APC/C proteins not
observed in PARP-1 immunoprecipitates have low
molecular weights (21 kDa and lower) and are therefore
more challenging to identify by mass spectrometry since
they generate fewer tryptic peptides upon digestion. This
is probably why they were not detected. Chang et al. [68]
demonstrated that PARP-1 is not critical for mitotic pro-
gression and that it does not play an essential role in the
regulation of anaphase entry in the cell cycle. However,
PARP-1 has been shown to bind and poly(ADP-ribo-Isabelle et al. Proteome Science 2010, 8:22
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syl)ate BUB3 [70], which is essential for the recruitment
of this protein to centromeric heterochromatin [71].
BUB3 is suggested to act as a regulator of the APC/C
complex. It is unclear how PARP-1 could be involved in
mitotic progression, but our findings motivate further
investigation of this potential function.
Conclusion
Affinity-purification mass spectrometry enabled us to
confirm and extend current knowledge on the interac-
tomes of PARP-1, PARP-2 and PARG, and provided a
global view of pADPr metabolism and of its various func-
tional ramifications. This study confirms the participa-
tion of DNA-dependent PARPs in complexes related to
multiple DNA damage pathways and suggests that PARP-
1 and PARP-2 may partake in other processes, notably
RNA metabolism (PARP-1, PARP-2) and the regulation
of the APC/C complex (PARP-1). Interactions between
PARG and multiple proteins involved in RNA metabo-
lism seem also highly likely. While building effective
mechanistic models covering all the functions of PARP-1,
PARP-2 and PARG will be a long and arduous process,
defining their interactomes is clearly the first step. Our
results complement the list of pADPr-binding proteins
and pADPr-associated proteins published by Gagne et al.
[29]. Taken together, these datasets provide the ground-
work for a system-wide modeling of the effects of
poly(ADP-ribosyl)ation on biological processes.
Materials and methods
Cell culture
Human neuroblastoma SK-N-SH and HeLa cervical car-
c i n o m a  c e l l  l i n e s  w e r e  c u l t u r e d  ( 5 %  C O 2 ,  3 7 ° C )  i n
DMEM medium supplemented with 10% foetal bovine
serum (Hyclone-ThermoFisher Scientific, Canada). Peni-
cillin (100 U/ml) and streptomycin (100 mg/ml) (Wisent,
Canada) were added to culture media.
Immunoprecipitation and immunoblotting
Cells were grown at 80-90% confluence in 150 mm cul-
ture dishes then washed with ice-cold phosphate-buff-
ered saline (PBS). Ice-cold phosphate lysis buffer (175
mM KPO4, pH 8.0, 150 mM NaCl, 1% NP-40, 1 mM
DTT, 0.5 mM PMSF, and Complete protease-inhibitor
cocktail, according to Roche diagnostics' instructions) or
Tris lysis buffer (175 mM Tris, pH 8.0, 150 mM NaCl, 1%
NP-40, 1 mM DTT, 0.5 mM PMSF, and Complete pro-
tease-inhibitor cocktail) was added to cells. Cells were
harvested using a cell scraper. Lysed cells collected from
three dishes were pooled, then gently mixed by inversion
for 1 hour at 4°C, and centrifuged for 10 min at 6000 × g
to remove insoluble cellular debris. The cellular extract
was mixed with magnetic beads coupled to protein G
(Dynal, Invitrogen, Canada) and the appropriate mono-
clonal antibody (F1-23 for PARP-1, M2 for FLAG-PARP-
2 and FLAG-PARG), or normal mouse IgG for the con-
trol, and incubated 2 hours at 4°C with rotation. The
beads had been previously blocked for 1 hour with 1%
BSA and washed with the appropriate lysis buffer. Pro-
teins were eluted from the beads by boiling for 5 min in
Laemmli SDS sample buffer containing 5% (v/v) β-mer-
captoethanol.
Eluted proteins were separated by SDS-PAGE and then
transferred onto 0.2 μm nitrocellulose membrane (Bio-
Rad, Canada). After one hour incubation with a blocking
solution (PBS-T containing 5% non-fat milk), the mem-
brane was probed overnight at 21°C with shaking, with
either: primary antibodies to PARP-1 [clone C2-10
(1:5000)], Apoptosis-inducing factor (AIF) [(1:5000),
Sigma, USA], ATP-dependent DNA helicase II 80 kDa
subunit (Ku80) [(1:5000), Oncogene Research Products,
USA], ATP-dependent DNA helicase II 70 kDa subunit
(Ku 70) [(1:5000), Oncogene Research Products, USA],
Bcl-2-associated transcription factor 1 (Btf) [(1:1000), BD
Pharmingen, USA], M2 [(1:1000), BD Pharmingen, USA],
Fragile-X mental retardation 1 protein (FMR-1) [(1:5000),
Chemica, USA], or Signal transducer and activator of
transcription 1-alpha/beta (STAT-1) [(1:2500), Cell Sig-
nalling, USA]. After washing with PBS-T (PBS containing
0.1% Tween-20), membrane were incubated for 1 hour
with species-specific horseradish peroxidase-conjugated
secondary antibody. Signals were detected with the West-
ern Lightning Chemiluminescence reagent plus kit (Per-
kin Elmer, USA).
LC-MS/MS analysis
Proteins eluted from the immunoprecipitated material
were separated by SDS-PAGE. The gel was then stained
with SYPRO Ruby fluorescent protein stain (Bio-Rad,
Canada) as per the manufacturer's instructions. The
entire protein profile on the gel was sliced into 30 sec-
tions using a gel excision Lanepicker (The Gel Company,
USA). In-gel protein digests were performed on a
MassPrep liquid handling station (Micromass, USA),
according to the manufacturer's instructions, using
sequencing-grade modified trypsin (Promega, USA).
Peptide extracts were dried out, resuspended in 10 μl of
0.1% formic acid in water, and analyzed by LC-MS/MS
using either an ion trap (LCQ Deca XP or LTQ, Thermo
Fisher, Canada) or a QqTOF (QStar XL, MDS Analytical
Technologies, Canada) mass spectrometer.
Ion trap analysis
Peptides were separated by reverse-phase liquid chroma-
tography and eluted into the spectrometer via a nanoelec-
trospray (nanoESI) ion source (all equipment from
Thermo Fisher). Peptide chromatography was achieved
with a BioBasic C18 PicoFrit column (75 μm ID × 10 cm,
New Objective, USA) at a flow rate of 200 nL/min with a
30-min linear gradient from 2 to 50% buffer B (ace-
tonitrile with 0.1% formic acid) against buffer A (waterIsabelle et al. Proteome Science 2010, 8:22
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Page 9 of 11
with 0.1% formic acid). Mass spectra were acquired using
a data-dependent acquisition mode whereby each MS-
only scan (400 to 2000 m/z) was followed by collision-
induced dissociation (CID) of either the three (LCQ) or
seven (LTQ) most intense ions. Dynamic exclusion was
set to 30 sec ND relative collisional fragmentation energy
to 35%.
qQTOF analysis
LC-MS/MS was performed using an Agilent 1100
nanoLC system coupled to a QSTAR XL equipped with
MDS's nanoESI source. Peptides were separated using the
aforesaid New Objective column running at 200 nL/min,
with a 25-min linear separation gradient from 2% to 25%
B followed by a 10-min linear gradient from 25% to 40% B
10 min (buffers A and B as above). Mass spectra were
acquired using a data-dependent acquisition mode
whereby each MS-only scan (400 to 1800 m/z) was fol-
lowed by CID of the three most intense ions having a +2,
+3 or +4 charge. Fragmented precursors were dynami-
cally excluded for 60 seconds with a 100-ppm mass toler-
ance.
Interpretation of MS/MS spectra and acceptance criteria for 
peptide and protein identifications
Ion trap MS/MS spectra were analyzed using Mascot [72]
(version 2.2.04, Matrix Science, UK) and SEQUEST (ver-
sion SRF v.2, Thermo Electron, USA) [73] whereas the
QqTOF MS/MS spectra were analyzed using Mascot and
X!Tandem (version TORNADO 2008.02.01.3, http://
www.thegpm.org) [74] which are more appropriate for
high mass accuracy datasets. SEQUEST, Mascot and
X!Tandem were set up to search the human IPI HUMAN
database (version 3.42, 72149 entries) assuming a diges-
t i o n  w i t h  t r y p s i n .  S e a r c h  p a r a m e t e r s  w e r e  a s  f o l l o w s :
fragment ion mass tolerance: 0.5 Da (Mascot, X!Tandem)
or 2.0 Da (SEQUEST); parent ion tolerance: 2.0 Da (all
search engines); fixed modification: carbamidomethyla-
tion of cysteine (all); variable modifications: oxidation of
methionine (all), deamidation of asparagines and glu-
tamine, and acetylation of lysine and arginine (Mascot
and X!Tandem only). Two missed cleavages were allowed.
Scaffold (version 2.2.1, Proteome Software, USA) was
used to validate MS/MS-based peptide and protein iden-
tifications. Peptide identifications were accepted if they
could be established at greater than 95.0% probability as
specified by the Peptide Prophet algorithm [75]. Protein
identifications were accepted if they could be established
at greater than 99.0% probability and contained at least 2
identified peptides. Protein probabilities were assigned by
the Protein Prophet algorithm [76]. Proteins that con-
tained similar peptides and could not be differentiated
based on MS/MS analysis alone were grouped to satisfy
the principles of parsimony. Using these stringent identi-
fication parameters, the rate of false positive identifica-
tions is less than 1%. Furthermore, any protein not
identified in at least two independent immunoprecipita-
tion experiments was discarded.
Clustering of identified proteins by biological processes
Proteins were classified as per the biological processes
ontology of the Gene Ontology (GO) [77] and hierarchi-
cal graphs of overrepresented GO terms were created
using BiNGO v2.0 [78] and Cytoscape v2.5 [79]. GO
annotations p-values were computed using the hypergeo-
metric statistical test (cluster versus the whole annotation
bank) and corrected with BiNGO's Benjamini and Hoch-
berg False Discovery Rate feature.
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